The application of immune checkpoint inhibitors, such as PD-1 and PDL-1, has shown efficacy against malignant melanoma, non-small cell lung cancer (NSCLC), and other tumours (Coleman et al., 2020). The gene discussed is CD274; the disease is non-small cell lung carcinoma.